Atai Life Sciences NV Form 4 insider transactions

Atai Life Sciences Chief Medical Officer, Craig Kevin James, executed a Rule 10b5-1 trading plan, involving option exercises and stock sales.

Gerd Kochendoerfer, Chief Operating Officer of Atai Life Sciences, reported transactions involving the sale of 50,000 common shares and the exercise of stock options.

Atai Beckley N.V. director Cosmo Feilding-Mellen's stock option award was amended, reducing shares to 10,000 but accelerating vesting to December 31, 2025.

Atai Beckley N.V. director Robert Hershberg was granted stock options following the acquisition of Beckley Psytech Limited.

Atai Beckley N.V. Director Cosmo Feilding-Mellen reported significant share and option acquisitions following the completion of the Beckley Psytech acquisition.

Atai Beckley N.V. Director Scott Braunstein was granted 56,818 stock options with an exercise price of $5.28, vesting fully on November 4, 2026.

ATAI Life Sciences N.V. has amended its Share Purchase Agreement for Beckley Psytech, adjusting share allocations and permitted transaction costs.

ATAI Life Sciences N.V. granted 175,000 stock options to its Chief Legal and Business Officer, Christopher Ryan Cave Barrett, with an exercise price of $5.20.

Apeiron Investment Group and Christian Angermayer filed a Form 4 detailing a planned conversion of convertible notes into 2.37 million common shares of ATAI Life Sciences N.V. on September 30, 2025.

Apeiron Investment Group and Christian Angermayer reported a significant purchase of ATAI Life Sciences common shares, increasing their beneficial ownership.

ATAI Life Sciences CEO Srinivas Rao's performance-based stock options, totaling 868,571 shares, have fully vested following the satisfaction of performance conditions.

ATAI Life Sciences N.V. Director Andrea Heslin Smiley was granted 103,000 stock options with an exercise price of $2.25, vesting by June 26, 2026, or the day before the next annual meeting.

ATAI Life Sciences N.V. Director Amir H. Kalali was granted 103,000 stock options with an exercise price of $2.25, vesting by June 26, 2026.

ATAI Life Sciences N.V. Director Sabrina Martucci Johnson was granted 103,000 stock options with an exercise price of $2.25, vesting by June 26, 2026, or earlier.

ATAI Life Sciences N.V. Director John Francis Hoffman was granted 206,000 stock options with an exercise price of $2.25, vesting over three years.

ATAI Life Sciences N.V. Director Laurent Fischer was granted 103,000 stock options with an exercise price of $2.25, aligning management interests with shareholder value.

ATAI Life Sciences N.V. Director Scott Braunstein was granted 103,000 stock options with an exercise price of $2.25, vesting by June 26, 2026, and expiring in 2035.

Christian Angermayer, a Director and 10% Owner of ATAI Life Sciences N.V., was granted 103,000 stock options with an exercise price of $2.25 per share.

ATAI Life Sciences N.V. has granted 131,698 stock options to Director and 10% owner Christian Angermayer, vesting over four years, tied to continued service and a voting agreement.

Sahil Kirpekar, Chief Business Officer of ATAI Life Sciences N.V., sold 48,563 common shares on March 21, 2025, at a price of $1.35 per share to cover tax liabilities arising from the vesting of restricted stock units.

Kevin James Craig, Chief Medical Officer of ATAI Life Sciences N.V., sold 11,563 common shares on March 21, 2025, at a price of $1.35 to cover tax liabilities related to vesting restricted stock units.

CEO Srinivas Rao sold 75,418 common shares of ATAI Life Sciences N.V. on March 21, 2025, at a price of $1.35 per share to cover tax liabilities related to vesting restricted stock units.

Anne Nagengast Johnson, CFO of ATAI Life Sciences N.V., sold 33,545 common shares on March 21, 2025, to cover tax liabilities arising from the vesting of restricted stock units.

Glenn Frank Short, Chief Scientific Officer of ATAI Life Sciences N.V., sold 13,161 common shares on March 21, 2025, at a price of $1.35 to cover tax liabilities related to vesting restricted stock units.

Apeiron Investment Group Ltd., a significant shareholder in ATAI Life Sciences N.V., has increased its holdings by purchasing 1,800,000 common shares for approximately $2.52 million.

Chief Medical Officer of ATAI Life Sciences, Kevin James Craig, reports the vesting and subsequent disposal of 20,000 common shares on March 14, 2025.

Glenn Frank Short, Chief Scientific Officer of ATAI Life Sciences N.V., reports the vesting of restricted stock units and subsequent acquisition of common shares on March 14, 2025.

Srinivas Rao, an officer of ATAI Life Sciences N.V., reports acquiring 175,000 common shares on March 14, 2025, through the vesting of restricted stock units.

Sahil Kirpekar, Chief Business Officer of ATAI Life Sciences N.V., reports the vesting and settlement of restricted stock units, resulting in the acquisition of 100,000 common shares.

Anne Nagengast Johnson, CFO of ATAI Life Sciences N.V., reports the vesting and conversion of restricted stock units into 100,000 common shares on March 14, 2025.